<DOC>
	<DOCNO>NCT00564512</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , work different way kill cancer cell stop grow . Monoclonal antibody , rituximab alemtuzumab , block cancer growth different way . Some find cancer cell help kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . It yet know whether give fludarabine cyclophosphamide together rituximab effective give fludarabine cyclophosphamide together alemtuzumab treat B-cell chronic lymphocytic leukemia . PURPOSE : This randomized phase III trial study give fludarabine together cyclophosphamide rituximab see well work first-line therapy compare give fludarabine together cyclophosphamide alemtuzumab treat patient B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Rituximab Alemtuzumab Treating CLL2007 CLL 2007 FMP</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare 36-month progression-free survival patient Binet stage B C B-cell chronic lymphocytic leukemia treat first-line therapy comprise fludarabine phosphate cyclophosphamide either rituximab alemtuzumab . Secondary - To compare disease-free survival , event-free survival , overall survival patient treat regimen . - To compare time next treatment patient treat regimen . - To compare overall response rate ( complete response [ CR ] partial response [ PR ] ) patient treat regimen . - To compare rate phenotypic molecular response patient treat regimen . - To compare duration phenotypic , molecular , complete partial response patient treat regimen . - To compare response rate survival time biological subgroup . - To compare rate treatment-related adverse effect patient treat regimen . - To compare quality life patient treat regimen . - Minimal residual disease study . OUTLINE : This multicenter study . Patients stratify accord Ig mutational status cytogenetic abnormality . Patients randomize 1 2 treatment arm . - Arm I : Patients receive rituximab IV day 1 fludarabine phosphate cyclophosphamide IV orally day 2-4 course 1 . Beginning course 2 subsequent course , patient receive rituximab IV day 1 fludarabine phosphate cyclophosphamide IV orally day 1-3 . - Arm II : Patients receive alemtuzumab subcutaneously , oral fludarabine phosphate , oral cyclophosphamide day 1-3 . In arm , treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) , meet follow criterion : Binet classification stage B C Del 17 p ( FISH ) negative ( &lt; 10 % positive core ) Matutes score 4 5 Exclusion Transformation aggressive Bcell malignancy ( e.g . diffuse large cell lymphoma , Hodgkin lymphoma , prolymphocytic leukemia ) PATIENT CHARACTERISTICS : Exclusion ECOG performance status â‰¥ 2 Life expectancy &lt; 6 month Creatinine clearance &lt; 60 mL/min Total bilirubin &gt; 2 x upper limit normal ( ULN ) Gamma glutamyltransferase transaminase level &gt; 2 x ULN Cumulative illness rating scale &gt; 6 HIV seropositivity Hepatitis B C seropositivity ( unless clearly due vaccination ) Clinically significant autoimmune anemia Active bacterial , viral , fungal infection Active second malignancy currently require treatment ( except basal cell carcinoma situ endometrial carcinoma ) and/or le 5 year complete remission breast cancer Any severe comorbid condition include , limited , follow : Class III IV heart failure Recent myocardial infarction Unstable angina Ventricular tachyarrhythmias require ongoing treatment Severe chronic obstructive pulmonary disease hypoxemia Uncontrolled diabetes mellitus Uncontrolled hypertension Concomitant disease require prolong use corticosteroid ( &gt; 1 month ) Known hypersensitivity anaphylactic reaction humanize monoclonal antibody study drug Contraindication use rituximab alemtuzumab accord Summary Product Characteristics Any coexist medical psychological condition would preclude participation require study procedures Any mental deficiency prevent proper understanding requirement treatment Person law control Pregnant breastfeed woman Fertile patient wish use effective method contraception , 12 month final treatment use purpose study PRIOR CONCURRENT THERAPY : Inclusion No prior chemotherapy , radiotherapy , immunotherapy CLL Corticosteroids within past month allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>